All In Biotech

Drug Trial Radar · NCT04815720

Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

A Phase 1b/2 Study of the Combination of Pepinemab and Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Last checked: Nov 19, 2026Latest source record: Jan 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

49

Actual

Start

Aug 9, 2021

Primary completion

Jul 24, 2024

Study completion Jul 24, 2024

Sponsor

Lead sponsor
Vaccinex Inc.Industry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Mar 25, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the safety and tolerability of pepinemab in combination with pembrolizumab as first-line treatment and determine a recommended Phase 2 dose (RP2D) in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Conditions

  • Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)

Interventions

  • pepinemab + pembrolizumabDrug

    The Safety Run-in phase will begin at 20 mg/kg pepinemab with a fixed dose of 200 mg pembrolizumab. The dose of pepinemab may be reduced to 15 mg/kg or 10 mg/kg with a fixed dose of 200 mg pembrolizumab if the initial pepinemab dose of 20 mg/kg is found to not be well tolerated. Once a recommended phase II dose of pepinemab is determined it will be utilized in the Dose Expansion phase in combination with 200 mg pembrolizumab.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects with Treatment Emergent Adverse Events (TEAE's).Time frame: 2 Years
  2. Evaluation of RP2DTime frame: 2 Years
  3. Efficacy EndpointTime frame: 2 Years

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Highlands Oncology Group, PA - North Hills

    Springdale, Arkansas

  • California Cancer Associates for Research and Excellence (CCARE)-Fresno

    Fresno, California

  • UCSF Medical Center at Mission Bay

    San Francisco, California

  • Yale Cancer Center

    New Haven, Connecticut

  • AdventHealth Celebration

    Celebration, Florida

  • AdventHealth Orlando

    Orlando, Florida

  • Emory Saint Joseph's Hospital

    Atlanta, Georgia

  • American Oncology Partners of Maryland, PA

    Bethesda, Maryland

  • Siteman Cancer Center - Washington University Medical Campus

    St Louis, Missouri

  • Northwell Health - Centers for Advanced Medicine

    Lake Success, New York

  • University of Rochester

    Rochester, New York

  • Messino Cancer Centers

    Asheville, North Carolina

  • Gabrail Cancer Research Center

    Canton, Ohio

  • Allegheny General Hospital

    Pittsburgh, Pennsylvania

  • Virginia Cancer Specialists - Fairfax

    Fairfax, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.